This biotech startup develops radiotracers that target GD2 cancer cell markers, enabling precise tumor mapping through medical imaging. By providing comprehensive visualization of therapeutic targets, the platform enhances patient selection for immunotherapy, improving treatment efficacy and minimizing unnecessary interventions.
Funding
$160K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods of analyzing the presence of target molecules in tumors, such as biopsies, provide a limited sample of the total tumor information, potentially leading to inaccurate diagnoses and hindering the effectiveness and safety of immunotherapies. Only a small fraction of the tumor is analyzed, and extrapolating results without knowing the whole presence of target molecules can be misleading. Furthermore, biopsies are invasive surgical procedures.
Solution
This biotech startup is developing radiotracers that enable comprehensive tumor mapping through medical imaging, highlighting areas vulnerable to immunotherapy. The radiotracers, composed of a radioactive isotope, a connector, and a carrier antibody, attach to target molecules of cancer cells. Once injected into the patient, these radiotracers distribute throughout the body and bind to the target molecules, allowing for the creation of a detailed map of all tumor cells potentially vulnerable to treatment. This mapping is visualized through medical imaging, revealing the exact location of target molecules and aiding in diagnosis and treatment planning.
Target Audience
The primary target audience includes oncologists and medical professionals seeking to improve the precision and efficacy of cancer immunotherapies through enhanced tumor visualization and target analysis.
Features
- Radiotracers composed of a radioactive isotope, connector, and carrier antibody
- Target molecule detection via radiotracer attachment to cancer cells
- Tumor mapping through medical imaging, visualizing vulnerable areas
- Non-invasive analysis of target molecules compared to biopsies
- Enhanced patient selection for immunotherapy
- Improved treatment efficacy and minimized unnecessary interventions